AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03208036 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Bridging Group
Description: Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
Study NCT03208036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging Group
Description: Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
Study NCT01702272 — intervention group
Intervention type: DEVICE
Intervention: Procleix Dengue Virus Assay
Description: in vitro diagnostic assay
Study NCT01511705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: Ondansetron Hydrochloride Tablets 8 mg
Study NCT01511705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: Zofran Tablets 8 mg
Study NCT03814772 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplant
Description: blood transfusion
Study NCT05458570 — intervention group
Intervention type: OTHER
Intervention: Breast Cancer positive patients
Study NCT04672785 — intervention group
Intervention type: BEHAVIORAL
Intervention: SF36 questionary
Description: patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
Study NCT02613234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathode tDCS
Description: At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).
Study NCT02613234 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cathode tDCS
Description: At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).
Study NCT00350103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 929
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use
Study NCT00350103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use
Study NCT01983189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: 1 hz transcranial magnetic stimulation
Study NCT05863728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery assisted group
Description: apicectomy will be done using the Piezosurgery device
Study NCT05863728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trephine Bur assisted group
Description: apicectomy will be done using the trephine burs
Study NCT05366036 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT02433574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic body radiation (SBRT)
Description: Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments.
Study NCT03598959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: orally 10 mg daily
Study NCT03598959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: orally 20 mg twice weekly
Study NCT01262027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: 500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
Study NCT04041453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
Study NCT04041453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Study NCT04041453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Study NCT03479762 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: No treatment given
Study NCT00929747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric
Description: Unilateral implantation of the AcrySof IQ Toric IOL
Study NCT00929747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal Relaxing Incision
Description: Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
Study NCT00490724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (1+0.01)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
Study NCT00490724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (2+0.005)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
Study NCT00490724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesritide (2+0.01)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
Study NCT00080678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00080678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Study NCT00080678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT02217956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00910234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin (rhEpo)
Description: rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study NCT00910234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin (rhEpo)
Description: rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study NCT03804970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash rewards for the fellow up
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study NCT00910234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study NCT03804970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Showing retinal photos to participants
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study NCT03804970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders for participants and their family
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study NCT01510405 — intervention group
Intervention type: OTHER
Intervention: Tissue Collection
Description: Tissue sample collection
Study NCT02873975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2606368
Study NCT00646724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cotransplantation of islet and mesenchymal stem cell
Description: islet of allograft and MSCs of autograft
Study NCT03804970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching brief video and basic explanation for disease
Description: This basic explanation will be offered by professional doctors or nurses.
Study NCT03804970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Having the Diabetic Club
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study NCT00794664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen
Description: 200 mg (1 mL), weekly subcutaneous injections for 26 weeks
Study NCT00794664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL weekly subcutaneous injections for 26 weeks
Study NCT00921323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-setting group
Description: This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
Study NCT04268927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH ant/letrozole
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study NCT04268927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH ant
Description: Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study NCT01998100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
Study NCT01998100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
Study NCT01998100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
Study NCT02998580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFR followed by HFL
Description: Magventure Cool B70 Coil with RX100 Stimulator
Study NCT02998580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS followed by iTBS
Description: Magventure Cool B70 Coil with RX100 Stimulator
Study NCT00733187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg
Study NCT02819557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: White to off-white powder for oral suspension.
Study NCT04668404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sonoclot
Description: Sonoclot machine
Study NCT00921323 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will be advised to continue to be physically active and record daily steps
Study NCT03504800 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
Study NCT01450488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 3 mg/kg/day
Study NCT01450488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 6 mg/kg/day
Study NCT01270477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Description: Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
Study NCT03532737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Adding PD-1 inhibitor to the standard of care
Study NCT04198935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Span Health Mobile Application
Description: A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
Study NCT01589315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focal ECT
Description: FEAST, ECT, unidirectional stimulation
Study NCT01850641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study NCT03999255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined respiratory support (CRS)
Description: combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
Study NCT00677898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered computerized tool
Description: A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
Study NCT00677898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written educational materials
Description: Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
Study NCT02344823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: per oral intake of 10mg Vardenafil once daily
Study NCT04787887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abcertin
Description: 60IU/kg Single Intravenous Administration
Study NCT02344823 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) baseline
Description: HVPG measurement day 1
Study NCT02344823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) baseline
Description: HVPG measurement day 1
Study NCT02344823 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) day 7
Description: HVPG measurement day 7
Study NCT02344823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) day 7
Description: HVPG measurement day 7
Study NCT02344823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline
Study NCT02344823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline
Study NCT02344823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
Study NCT02344823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
Study NCT02344823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intake once daily
Study NCT00094445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
Study NCT00175227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous saline hydration + mannitol + furosemide
Description: 500 mls half-normal saline + 25g mannitol + 100 mg furosemide
Study NCT00175227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous saline hydration
Description: 500 mls half-normal saline
Study NCT04787887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Cerezyme
Description: 60IU/kg Single Intravenous Administration
Study NCT01521000 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Garment Sleeve
Description: compression sleeve (20 to 30 mm of Hg)
Study NCT01521000 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Garment Sleeve
Description: compression sleeve (20 to 30 mm of Hg)
Study NCT04572373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: SMOFlipid
Study NCT03516565 — intervention group
Intervention type: OTHER
Intervention: Saliva collection
Study NCT00589121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
Study NCT03516565 — intervention group
Intervention type: OTHER
Intervention: GCF collection
Study NCT03251365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC-gemcitabine
Description: • Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
Study NCT03416348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum Chloride 20% (deodorant)
Description: Aluminum Chloride (deodorant)
Study NCT03416348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Chloride 20% (deodorant)
Description: Aluminum Chloride (deodorant)
Study NCT03416348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Placebo
Study NCT03416348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Placebo